TGTX - TG Therapeutics Inc Company Long-Term Liabilities

High risks associated with competing against pharma behemoths are weighing on the credit profile of TG Therapeutics, Inc. (TGTX). The trajectory of the business's long-term debt demonstrates pricing resilience, where the value of 0.78 captures the metric level. Financial stability relies on integration with onco-hematology medical centers and the effective outsourcing of drug production to third-party contractors, which minimizes production disruptions.

Long-term liabilities measure the volume of multi-year borrowings, allowing for an assessment of financial stability and the cost of capital servicing over the long term. By analyzing the time series of long-term debt for TG Therapeutics, Inc. (TGTX), an investor can determine how effectively the credit resources of TG Therapeutics, Inc. (TGTX) were transformed into the commercial success of the drug Briumvi, offsetting decades of R&D expenditures through the high margins of molecular synthesis.